ES2929570T3 - Células B para administración in vivo de agentes terapéuticos - Google Patents

Células B para administración in vivo de agentes terapéuticos Download PDF

Info

Publication number
ES2929570T3
ES2929570T3 ES15871244T ES15871244T ES2929570T3 ES 2929570 T3 ES2929570 T3 ES 2929570T3 ES 15871244 T ES15871244 T ES 15871244T ES 15871244 T ES15871244 T ES 15871244T ES 2929570 T3 ES2929570 T3 ES 2929570T3
Authority
ES
Spain
Prior art keywords
cells
cell
cd40l
antibody
vitro method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15871244T
Other languages
English (en)
Spanish (es)
Inventor
Matthew Rein Scholz
Eric J Herbig
Mei Xu
Laat Rian De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusoft Corp
Original Assignee
Immusoft Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusoft Corp filed Critical Immusoft Corp
Application granted granted Critical
Publication of ES2929570T3 publication Critical patent/ES2929570T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
ES15871244T 2014-12-19 2015-12-18 Células B para administración in vivo de agentes terapéuticos Active ES2929570T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094794P 2014-12-19 2014-12-19
US201562110063P 2015-01-30 2015-01-30
PCT/US2015/066908 WO2016100932A1 (en) 2014-12-19 2015-12-18 B cells for in vivo delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
ES2929570T3 true ES2929570T3 (es) 2022-11-30

Family

ID=56127743

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15871244T Active ES2929570T3 (es) 2014-12-19 2015-12-18 Células B para administración in vivo de agentes terapéuticos

Country Status (6)

Country Link
US (2) US20180002664A1 (pl)
EP (2) EP4177336A1 (pl)
DK (1) DK3234107T3 (pl)
ES (1) ES2929570T3 (pl)
PL (1) PL3234107T3 (pl)
WO (1) WO2016100932A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
JP2019526270A (ja) * 2016-09-12 2019-09-19 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ゲノム編集初代ｂ細胞ならびに作製方法および使用方法
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
BR112019015355A2 (pt) * 2017-01-26 2020-05-19 Sangamo Therapeutics Inc modificação genética de células b
BR112019022473A2 (pt) * 2017-04-27 2020-10-20 Immusoft Corporation células b para liberação in vivo de agentes terapêuticos e dosagens destas
GB201707238D0 (en) 2017-05-05 2017-06-21 Univ Oxford Innovation Ltd Composition
EP3765601A1 (en) * 2018-03-16 2021-01-20 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
WO2020197984A1 (en) 2019-03-22 2020-10-01 Albany Medical College Methods for improving cognitive function
US20240124561A1 (en) * 2019-10-17 2024-04-18 Minicircle Inc. Nucleic acids encoding hiv neutralizing antibodies and uses thereof
US12195723B2 (en) * 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
CN115003314A (zh) * 2019-11-27 2022-09-02 得克萨斯大学体系董事会 B细胞的大规模组合car转导和crispr基因编辑
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
WO2022051556A1 (en) * 2020-09-02 2022-03-10 Walking Fish Therapeutics Modified b cells and methods of use thereof
WO2022094284A1 (en) * 2020-10-30 2022-05-05 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
EP4326289A4 (en) * 2021-04-19 2025-03-12 Walking Fish Therapeutics, Inc. Methods of b cell expansion for use in cell therapy
JP2025506058A (ja) * 2022-02-16 2025-03-05 ステムセル テクノロジーズ カナダ インコーポレイテッド リンパ球を増殖させるための組成物及び方法
WO2024040201A1 (en) * 2022-08-19 2024-02-22 Celdara Medical Llc Improved method and system for cell therapy
CN120917139A (zh) * 2023-04-05 2025-11-07 豪夫迈·罗氏有限公司 用于抗体表达细胞的体外培养方法
WO2025106856A1 (en) 2023-11-15 2025-05-22 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy
WO2025147573A2 (en) 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease
WO2026085108A2 (en) 2024-10-14 2026-04-23 Immusoft Corporation B cell compositions and methods of use
CN120779030B (zh) * 2025-09-11 2025-11-28 天津医科大学总医院空港医院 用于淋巴组织微环境中eb病毒和浆细胞的检测试剂盒及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
JPH0276820A (ja) * 1988-06-15 1990-03-16 Ajinomoto Co Inc 骨髄移植療法支持剤
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
DE4223128C2 (de) 1991-07-15 1995-06-14 Handtmann Albert Maschf Verfahren und Vorrichtung zum Vereinzeln und Aufbringen einer Darmraupe auf ein Füllrohr
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1995004521A1 (en) 1993-08-10 1995-02-16 W.L. Gore & Associates, Inc. Cell encapsulating device
ATE277081T1 (de) 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1996039993A1 (en) 1995-06-07 1996-12-19 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1997010807A1 (en) 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
JP4881536B2 (ja) 2001-02-15 2012-02-22 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 細胞死を調節する細胞障害性因子
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
CA2438500C (en) 2001-02-19 2009-09-08 Pola Chemical Industries Inc. Composition for electroporation
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
WO2007059332A2 (en) * 2005-11-17 2007-05-24 Biogen Idec Ma Inc. Platelet aggregation assays
NZ592159A (en) * 2005-12-09 2012-12-21 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
US7799555B2 (en) 2006-02-10 2010-09-21 Bio-Rad Laboratories, Inc. Apparatus for high-throughput electroporation
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US8551780B2 (en) 2008-02-01 2013-10-08 H. Lee Moffitt Cancer Center & Research Institute, Inc. Electroporation buffer composition and method of use
US8133727B2 (en) 2008-11-21 2012-03-13 California Institute Of Technology In vitro human B lymphopoiesis culture system
US9074223B2 (en) 2010-01-08 2015-07-07 Immusoft Corporation Vectors and methods for transducing B cells
US8633029B2 (en) 2010-03-15 2014-01-21 Yamaguchi University Agent for improving gene transfer efficiency to mammalian cells
CA2806858C (en) * 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
PL2790712T3 (pl) * 2011-12-14 2017-04-28 Yeda Research And Development Co. Ltd. Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors

Also Published As

Publication number Publication date
EP3234107A4 (en) 2018-07-04
PL3234107T3 (pl) 2023-01-16
EP3234107B1 (en) 2022-09-14
CA2971430A1 (en) 2016-06-23
EP3234107A1 (en) 2017-10-25
HK1245834A1 (en) 2018-08-31
US20230081163A1 (en) 2023-03-16
DK3234107T3 (da) 2022-10-17
WO2016100932A1 (en) 2016-06-23
US20180002664A1 (en) 2018-01-04
EP4177336A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
ES2929570T3 (es) Células B para administración in vivo de agentes terapéuticos
JP7499798B2 (ja) インビトロでのメモリーｂ細胞分化方法およびｖｓｖ－ｇ偽型ウイルスベクターを用いる形質導入方法
ES2617749T3 (es) Vectores y procedimientos para la transducción de linfocitos B
US20220193129A1 (en) B cells for in vivo delivery of therapeutic agents and dosages thereof
CA2971430C (en) B cells for in vivo delivery of therapeutic agents
HK1245834B (en) B cells for in vivo delivery of therapeutic agents
HK1178934A (en) Vectors and methods for transducing b cells
HK1178934B (en) Vectors and methods for transducing b cells
HK1220230B (en) Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors